Treatment extension with Adjuvant Aromatase Inhibitor to 10 years results in significantly higher rates of disease free survival
34% lower risk of disease recurrence. 
Safe and beneficial for postmenopausal women.
Ref:  Extending Aromatase inhibitor Adjuvant Therapy to 10 years. June 5,2016, at nejm.org.
Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions.Read more
Colorectal cancer is a major cause of morbidity and mortality, being one of the most common malignant tumors in the world.Read more
Cancer of the prostate is the most common malignancy in elderly menRead more
Chemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy.Read more